Dr Tan See Leng was appointed the Managing Director and Chief Executive Officer of IHH Healthcare Berhad ("IHH") in January 2014 after serving as an Executive Director on the IHH Board for two years. Dr Tan is also the Group CEO and Managing Director of Parkway Pantai Limited, a position he assumed in 2011. He also serves on the Boards of IHH subsidiaries, namely Parkway Pantai Limited, Fortis Healthcare Limited, SRL Limited and Acibadem Saglik Yatirimlari Holding A.S. ("ASYH") Group and on a Board Committee of ASYH. He also serves on the Advisory Board of Lee Kong Chian School of Business at Singapore Management University and on the Board of Parkway Trust Management Limited ("PTM"), an indirect whollyowned subsidiary of IHH. PTM manages Parkway Life Real Estate Investment Trust, which is listed on the Singapore Exchange Securities Trading Limited.
Prior to this, Dr Tan was the CEO of Parkway Holdings Limited from April 2010, a position he rose to fairly quickly after he joined Parkway in 2004 as Chief Operating Officer of Mount Elizabeth Hospital. As a young entrepreneur, Dr Tan founded a private primary healthcare group at the age of 27 and subsequently developed it into the second largest primary healthcare group in Singapore before successfully selling the company to a leading global health-plan and insurance provider.
With over 27 years of healthcare experience, Dr Tan has served as an active member of various medical committees, such as Singapore Ministry of Health's MediShield Life Review Committee. He has been re-appointed Adjunct Assistant Professor of Duke-NUS Graduate Medical School Singapore, Office of Education, for the period until 2019.
Dr Kelvin Loh Chi-Keon was appointed the Chief Executive Officer ("CEO") (designate) and Executive Director of IHH Healthcare Berhad ("IHH") on 1 July 2019 and will assume the position of Managing Director and CEO of IHH Healthcare with effect from 1 January 2020.
Dr Loh started his career as a practising physician after a decade in the public sector in areas such as clinical services development, hospital planning and hospital operations. Dr Loh first joined the IHH Group in 2008. Between 2008 and 2017, he held a number of senior management roles, before taking over as CEO for its Singapore Operations Division, covering among other services, the 4 multi-specialty tertiary hospitals - Mount Elizabeth Orchard, Mount Elizabeth Novena, Gleneagles and Parkway East.
In 2017, Dr Loh moved to Columbia Asia Group as CEO where he was responsible for overseeing Columbia Asia Group's 28 hospitals across 4 countries in Asia, before he rejoined IHH.
With more than 20 years' experience in the healthcare industry and a strong track record of delivery, Dr Loh is a senior healthcare executive with extensive experience in leading large healthcare businesses, building relationships with stakeholders, managing hospital operations, financial management and developing talent.
An expert in lean management systems, Dr Loh was previously a member of Singapore's National Expert Advisory Panel for Healthcare Productivity and Advisor to the Asia Productivity Organisation. Dr Loh was also a Visiting Lecturer for the Master of Public Health and Master of Business Administration programmes at the National University of Singapore.
Dr Loh holds a Medical Degree and a Master of Business Administration from the National University of Singapore.
Mr Low Soon Teck assumed the position of Group Chief Financial Officer of IHH Healthcare Berhad ("IHH") on 10 January 2016. He brings with him over 20 years of experience in finance, legal and general management in leadership roles.
Prior to joining IHH, Mr Low served with the RCMA Group, a commodities supply chain management company, as its Chief Financial Officer between 2013 and 2015. From 1994 to 2013, he was employed in the Kuok/Kerry Group, holding various senior positions in diverse businesses within the group in Hong Kong and Singapore. His last position in the group was as Chief Financial Officer of the PACC Offshore Services Holdings Group, the offshore marine arm of the Kuok/Kerry Group. Prior to this, Mr Low served as Group Treasurer at Wilmar International Limited, after its merger in 2006 with Kuok Oils and Grains where he had served as Group Financial Controller following his relocation from Hong Kong to Singapore in 2005.
Whilst Mr Low was based in Hong Kong from 1994 to 2005, he held various positions within the Kerry Group, including that of Director of China Operations at SCMP Group, publisher of the South China Morning Post. In these roles, he was responsible for business development, newspaper publishing and circulation operations, as well as managing a chain of retail convenience stores.
Mr Low began his career as a solicitor in Singapore at a boutique law firm from 1991 to 1993, focusing on corporate and banking laws.
Dr Lim Suet Wun is the Group Chief Operating Officer of IHH Healthcare Berhad ("IHH").
He brings more than 30 years of experience in healthcare management. Dr Lim has served Parkway Pantai since 2011, first as Executive Vice President Singapore and then as the Chief Executive Officer, Parkway Operations Division, before assuming the role of Group COO of Parkway Pantai.
Prior to joining Parkway, Dr Lim was the CEO of the National Healthcare Group and Tan Tock Seng Hospital (TTSH). In 2003, Dr Lim led the TTSH team through the SARS crisis, when the hospital was designated the SARS hospital for the whole of Singapore. For his leadership, he was awarded the Public Service Star by the President of Singapore. Dr Lim was also the former chairman of the Board of Joint Commission International (JCI).
Dr Chan has more than 20 years of healthcare management experience. He had a long association with IHH and its predecessor entity Parkway Healthcare from 2000–2010. Among the various positions held, he was the interim Group Chief Executive Officer of Pantai Holdings Berhad. He returned to IHH in 2018 to lead IHH Strategic Planning and Business Development (M&A) and the CEO for South East Asia Operations. Additionally, he is a Director of Fortis Healthcare Ltd (listed on the India Stock Exchange) and RHT Health Trust Pte. Ltd (listed on the SGX).
Prior to joining IHH in 2018, he was a senior advisor to a private equity investment firm. From 2010–2016, he was the Group President of Sasteria Pte Ltd, a privately held healthcare entity, which owns Thomson Medical Group based in Singapore and TMC Life Sciences based in Kuala Lumpur, Malaysia. He concurrently served as the Group CEO of Thomson, as well as the Executive Director of TMC Life Sciences Limited. Dr Chan had also served as an Advisor to a sovereign wealth fund based in Abu Dhabi.
Professor Abdul Aziz Baba was promoted as the President of IMU Health Sdn Bhd, a wholly-owned subsidiary of IHH Healthcare Berhad ("IHH"), on 1 January 2018. Since 1 January 2016, he is also the Chief Executive Officer and Vice-Chancellor of IMU Education Sdn Bhd, a wholly-owned subsidiary of IHH, responsible for operating the International Medical University ("IMU"). Prior to assuming this role, Prof Aziz served as Vice President of IMU since 1 November 2013, a role he was promoted to since joining IMU in 1 July 2013 as Vice President with responsibility for the Medical and Dental Programme.
Before he joined IMU, Prof Aziz held several key academic administrative positions at the School of Medical Sciences (SMS) of Universiti Sains Malaysia (USM). These included the positions of Dean (2005–2012) and Deputy Dean (2003–2005). Preceding this he served as a Professor (2000), Associate Professor (1992) and Lecturer and Clinical Haematologist/ Oncologist at USM's SMS, following the completion of his postgraduate training in 1986. During his tenure with USM, Prof Aziz was instrumental in establishing the Clinical Haematology and Stem Cell Transplantation service at USM's teaching hospital, HUSM.
Prof Aziz undertook his undergraduate medical training at the University of Melbourne on a Colombo Plan scholarship and graduated in November 1979. He subsequently trained in Internal Medicine, Haematology and Medical Oncology at several leading overseas institutions in Singapore, Scotland and Melbourne, Australia.
His past national appointments include those of President of the Malaysian Society of Haematology and Chairman of the National Conjoint Board for Postgraduate Medical Programmes, as well as Chairman of the Specialist Advisory Committee (Clinical Haematology) of the National Specialist Register. Prof Aziz has also been a member of the Malaysian Medical Council (MMC) and has served the MMC on several accreditation visits to local and foreign medical institutions. Currently he serves as a member of the Joint Technical Committee of the Malaysian Medical Council, the Executive Committee of the National Cancer Council Malaysia (MAKNA) and the Vice Chancellor's Council for Private University (VCCPU).
Ms Sharon Teo Fay Lin joined IHH Healthcare Bhd ("IHH") on 10 March 2017. She is a Human Resources practitioner with more than twenty years' HR experience across a broad spectrum of pharmaceutical, manufacturing and FMCG MNCs and local enterprises.
Prior to joining IHH, Ms Teo served with Avery Dennison Singapore Pte Ltd in various positions, beginning as the HR Director for its' ASEAN business before leading Integration and Transformation at the East Asia and Pacific level. She was subsequently promoted as the HR Director for the Materials Group at the ASEAN level.
Preceding this, Ms Teo held senior positions in pharmaceutical and healthcare MNCs, such as Novartis Asia Pacific Pharmaceutical Pte Ltd, where she served as the Human Resources Manager and Regional Human Resources Manager, Asia Pacific before being promoted as the Head of Talent Management, Organization Development and Staffing, Asia Pacific. Prior to that, she served at Bausch & Lomb Sdn Bhd as the Regional Human Resources Administrator, South Asia before rising to the position of Human Resources and Administration Manager, Malaysia and Singapore. Ms Teo began her career at Yeo Hiap Seng (M) Berhad as a Human Resources Executive in 1993.
Ms Audrey Huang was appointed the Group Head of Internal Audit of IHH Healthcare Berhad ("IHH") on 1 March 2013. In this position, she is responsible for managing the internal audit functions of the Group's overall system of internal controls, risk and governance.
Ms Huang brings to the table more than 30 years experience in auditing, including external audit experience with one of the big four accounting firms as well as internal audit experience with various financial institutions.
Prior to joining IHH, Ms Huang had served as the Head of Internal Audit of Parkway Pantai Limited following its incorporation on 21 March 2011. Before that, she was Head of Internal Audit of Parkway Holdings Limited from 21 February 2005.
In 2013, she obtained the Certification in Risk Management Assurance ("CRMA") from the Institute of Internal Auditors, Inc USA, thereby strengthening her portfolio of skills.
Ms Nili Shayrina binti Saat has more than 20 years of experience in Risk Management with broad industry experiences across property development, constructions, media, oil and gas, hotel, education and agriculture with regional exposure in Indonesia, Thailand, Singapore, India and the Middle East.
Prior to joining IHH in 2018, she was the Director of Business Process and Risk Management for Eagle Hills Properties in Abu Dhabi and oversaw the risk management and business process improvement functions. Preceding this she was the Innovation Chief of Iskandar Investment, spearheading the Innovation initiatives for the organisation.
Mr Tahsin Güney was appointed as the Chief Executive Officer of Acibadem Saglik Yatirimlari Holding A.S on 1 March 2019. He is a highly experienced healthcare professional with deep knowledge on hospital operations and management. He first joined Acibadem in 2008 as Planning and Business Development Director and has served as Deputy General Manager since 2013.
Armed with a Bachelor's degree in Public Administration and a Master's degree in Actuarial Science and Statistics, Mr Tahsin Güney started his career in 1990 as an Assistant Inspector at Turkey's Social Security Agency, where he rose through the ranks to become Acting President and Acting President of the Board in 2008.
Ida possesses vast experience in legal and corporate secretarial fields, having worked as in-house legal counsel and company secretary of MNC and public-listed companies. Immediately prior to joining IHH, Ida was the Chief Counsel of FGV Holdings Berhad (FGV) since December 2017 . Over her seven and a half years stint with FGV, she had held various positions including as Vice President of Sustainability & Environment, Group Governance and Compliance, International Business and Group Company Secretary of FGV.
Ida was admitted to the High Court of Malaya as an advocate and solicitor in 1997.